Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Afferent Pharmaceuticals
San Mateo, California, United Statesafferentpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Afferent Pharmaceuticals developed first-in-class small molecule antagonists of the P2X3 receptor for neurogenic conditions. Its lead candidate, AF‑219 (gefapixant), showed robust reductions in cough frequency in Phase 2b trials for chronic cough and was also studied in IPF with cough. The company’s second compound, AF‑130, completed Phase 1 testing and was planned for further studies in non-respiratory indications. In June 2016, Merck acquired Afferent to advance these programs into later-stage clinical development.[10][9]
- Therapeutic areas
- PulmonologyCardiovascularNeurology
- Modalities
- Small molecules[6][9][10]
- Industry
- Biotech
Beyond the preview
Go deeper on Afferent Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Afferent Pharmaceuticals.